NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01216644,"5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer",https://clinicaltrials.gov/study/NCT01216644,,COMPLETED,"Patients with locally advanced resectable adenocarcinoma of the stomach or the esophagogastreal junction without previous therapy will be treated with one of two chemotherapy combinations before and after surgery. One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT), the others Epirubicin, Cisplatin and 5-FU (ECF). Main objective of the study is median overall survival.",NO,Gastric Cancer,DRUG: 5-Fluorouracil|DRUG: Leucovorin|DRUG: Oxaliplatin|DRUG: Docetaxel|DRUG: Epirubicin|DRUG: Cisplatin|DRUG: 5-fluorouracil,"median overall survival, 2 years follow-up","histopathological regression rate, 6 weeks after surgery|disease free survival (DFS), 2 years follow-up|correlation of pCR and DFS with survival, 2 years follow-up|Perioperative Morbidity and Mortality, up to 2 months after surgery|R0-Resection rate, 2 months after surgery",,Krankenhaus Nordwest,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,716,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,FLOT4,2010-08,2017-03,2019-05,2010-10-07,,2019-06-19,"Krankenhaus Nordwest, Frankfurt, 60488, Germany",
